JMP Securities Maintains Bullish View on BioCryst Pharma (BCRX) After Orladeyo Approved in the EU
Tweet Send to a Friend
JMP Securities analyst Jonathan Wolleben reiterated a Market Outperform rating and $16.00 price target on BioCryst Pharma (NASDAQ: BCRX) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
